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Distinctive pattern of temporal 
atrophy in patients with 
frontotemporal dementia and 
the I383V variant in TARDBP
INTRODUCTION
Frontotemporal dementia (FTD) and 
amyotrophic lateral sclerosis (ALS) are 
closely related disorders, linked patho-
logically and genetically by the TAR 
DNA- binding protein-43 (TDP-43). 
Pathogenic variants in TARDBP encoding 
for TDP-43 have been described less 
frequently in FTD than in ALS, and clin-
icopathological studies are scarce.1 We 
previously observed a high frequency 
of the I383V variant in TARDBP in a 
Dutch cohort of FTD patients.2 Here, we 
provide further evidence for the patho-
genicity of this variant and present its 
clinicopathological characteristics.
METHODS
We ascertained all FTD (n=13) and 
ALS patients (n=4) with the I383V 
variant (NM_007375.3: c.1147A>G, 
p.Ile383Val) in TARDBP from three 
university medical centres in the Neth-
erlands (Amsterdam, Rotterdam and 
Utrecht), as identified by whole- exome 
or whole- genome sequencing in either 
clinical or research setting. Concurrent 
pathogenic variants in 20 other genes 
associated with ALS, FTD or other forms 
of dementia were excluded in all patients.
Brain imaging (CT or MRI) was 
available for all FTD patients. Quanti-
tative assessment of volume loss across 
lobar brain regions was performed in 
those patients with T1- weighted MRI 
images of sufficient quality (n=5), and 
compared with a gender- matched/age- 
matched reference population.
Family histories were classified into 
adjusted Goldman categories, which were 
described previously.2 Additionally, we 
performed extensive genealogical research 
to investigate possible relatedness between 
the index patients.
Brain autopsy and routine immunohis-
tochemistry was performed for two FTD 
patients by the Netherlands Brain Bank. 
One patient (4M) was reported previ-
ously as M008015-001.1 Detailed infor-
mation on the genetic, neuroimaging, 
genealogical and pathological analyses 
can be found in the1.
RESULTS AND DISCUSSION
The variable clinical phenotype and 
reduced penetrance of the I383V variant
All 13 FTD patients with the I383V variant 
in TARDBP presented with a combination 
of behavioural changes and semantic defi-
cits. The diagnoses of semantic variant of 
primary progressive aphasia (svPPA) are 
intriguing since this is usually considered 
a sporadic disorder. One patient (4M) 
showed additional motor symptoms, but 
not fulfilling ALS criteria. Of the 4 ALS 
patients with the I383V variant, 3 had 
a relatively slow progression with the 
longest disease duration of 9 years. None 
of the ALS patients exhibited cognitive or 
behavioural symptoms. Clinical details are 
presented in online supplemental tables 
1,2.
Six FTD patients and one ALS patient 
were found to be related (family 1). 
Additionally, two FTD patients and two 
ALS patients (families 2 and 3) could 
be linked to family 1 through a distant 
common ancestor (figure 1). The variable 
phenotype of the I383V variant is exem-
plified by family 1, in which different 
family members were affected by svPPA, 
behavioural variant of FTD, unspeci-
fied dementia, ALS or progressive spinal 
muscular atrophy, with a wide range in 
age at onset (44–69 years) and disease 
duration (7–23 years). Interestingly, 
several obligate carriers were unaffected, 
suggesting incomplete penetrance even 
at an advanced age (>80 years). Larger 
prospective studies are required to esti-
mate age- related penetrance.
Four remaining families (online supple-
mental figure 1) did not show a clear 
pattern of autosomal dominant inheritance 
(Goldman 2–5). In one of these families, 
an affected relative with the I383V variant 
was clinically diagnosed with Alzheimer’s 
disease (AD), but AD biomarker changes 
were not evaluated in cerebrospinal fluid. 
A possible explanation is that the dementia 
in this patient is coincidental and unre-
lated to the I383V variant. Alternatively, 
increased susceptibility for AD caused 
by the I383V variant may be considered. 
Another interesting hypothesis is that 
TARDBP variants might be associated with 
limbic- predominant age- related TDP-43 
encephalopathy, a common age- related 
disorder with TDP-43 proteinopathy that 
clinically mimics AD.3
Several other relatives, including obli-
gate carriers, were affected by psychiatric 
disorders such as psychosis and schizo-
phrenia with onset around 40–50 years. 
Unfortunately, detailed clinical informa-
tion or DNA were not available for these 
subjects. Whether psychiatric disorders 
are part of the I383V–TARDBP spec-
trum remains to be investigated in future 
studies. Altogether, our observations illus-
trate large phenotypic variability of the 
I383V variant and incomplete penetrance.
Isolated bitemporal atrophy in FTD 
patients with the I383V variant
The most discriminating feature of the 
I383V variant is the predominant and 
severe atrophy of the temporal lobes in 
all FTD patients, with relative sparing 
of the other lobes (figure 1 and online 
supplemental figure 2). This is in line 
with previous observations in I383V FTD 
patients and the frequent occurrence of 
semantic deficits and prosopagnosia in 
our patients (online supplemental table 1). 
Other pathogenic TARDBP variants (eg, 
K263E) are associated with a more vari-
able pattern of lobar atrophy.1 However, 
predominant temporal involvement has 
also been reported for other TARDBP 
variants located nearby the I383V variant 
(eg, A382T),4 suggesting a specific effect 
of missense variants in this part of the 
C- terminal domain of TDP-43. Further 
functional studies are needed to eluci-
date these possible genotype–phenotype 
correlations.
Heterogeneous pathological features in 
TARDBP patients
A remarkable observation is the scarcity 
of TDP-43 reactivity in the cortical areas 
of two FTD patients (patient 1F and the 
previously reported patient 4M1), despite 
the underlying pathogenic TARDBP 
variant. Only several TDP-43 cytoplasmic 
inclusions of various morphologies were 
found in the frontal cortex, dentate gyrus 
and caudate nucleus (figure 1). A possible 
explanation for the scarce temporal 
pathology might be the severe neurode-
generation, especially considering the long 
disease duration of patient 1F (23 years). 
Interestingly, we also detected tau positive 
inclusions in the hippocampus and tufted 
astrocytes in the putamen and caudate 
nucleus (figure 1). A single other neuro-
pathological study of a I383V carrier 
reported similar low amounts of TDP-43 
inclusions, and the presence of α-synuclein 
deposits and tauopathy, including tufted 
astrocytes in the amygdala.5 It appears that 
the neuropathological changes in FTD 
caused by variants in TARDBP are not 
readily classifiable. Whether the detected 
co- pathologies occurred by chance needs 
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Classification of the I383V variant as 
likely pathogenic
Our findings indicate a pathogenic effect 
of the I383V variant, which was previously 
debated due to the more conservative 
amino acid substitution and the benign in 
silico predictions by SIFT and PolyPhen. 
The current families, especially family 1, 
clearly show segregation of the variant 
with the disease, although penetrance 
appears incomplete. In addition to the 
patients described here, the I383V variant 
has been previously reported in 16 FTD 
and 8 ALS patients (online supplemental 
table 3), with frequencies ranging from 
0% to 0.9% in ALS cohorts and from 0% 
to 2.5% in clinical FTD cohorts, while 
the variant is consistently absent in large 
groups of healthy controls from different 
populations. These data additionally 
support its pathogenicity. This conclu-
sion has clinical implications for genetic 
counselling of patients and unaffected 
family members, to whom presymptom-
atic testing and counselling can now be 
offered.
Figure 1 Pedigree of families 1–3 with radiological and pathological features. 
Upper panel: three families were found to have a common ancestor following genealogical research. These families include 8 FTD patients and 3 ALS 
patients with a confirmed I383V variant in TARDBP (numbered A–K; fully coloured). Half coloured symbols represent patients with a clinical diagnosis 
without genetic testing. Red: clinical diagnosis of FTD or PPA. Black: clinical diagnosis of ALS or PSMA. Grey: relatives of index patients affected by other 
forms of dementia or psychiatric disorders. Numbers inside symbols represent additional family members without further clinical information. Numbers 
below the symbols indicate age at death or current age. Clinical diagnoses: bvFTD, behavioural variant of frontotemporal dementia; svPPA, semantic variant 
of primary progressive aphasia; ALS, amyotrophiclateral sclerosis; PSMA, progressive spinal muscular atrophy; UD, unspecified dementia; Psych, psychiatric 
disorder; NA, not affected based on family history; unk, disease status unknown. *Neuropathological examination (patient 1F).  
Lower left panel: neuroimaging of three FTD patients with the I383V variant showing predominant bitemporal atrophy. MRI scans were obtained 7 years 
(1C), 6 years (1E) and 9 years (2H) after symptom onset. Quantitative analysis of volumetric loss per brain region is shown in online supplemental figure 2.  
Lower right panel: immunohistochemistry of patient 1F revealed several pTDP-43 positive neuronalcytoplasmic inclusions (NCI) of various morphologies 
in the frontal cortex (A) and nucleus caudate (B). Compared to other FTD- TDP cases, the amount of inclusions is low and intranuclear inclusions were not 
found. Therefore, this patient could not be readily classified into one of the FTLD- TDP subtypes. Staining with AT8 antibody revealed NCI in the hippocampus 
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CONCLUSION
Our study provides sufficient evidence for 
the pathogenicity of the I383V variant 
and contributes to the characterisation of 
TARDBP- related FTD. We demonstrate 
the large phenotypic variability and incom-
plete penetrance of the I383V variant. 
Marked isolated bitemporal volume loss 
in all FTD patients should prompt clini-
cians to genetically test for causal variants 
in TARDBP.
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